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Abstract
Huntington's disease (HD) is one of the most common autosomal dominant inherited,
neurodegenerative disorders. It is characterized by progressive motor, emotional and cognitive
dysfunction. In addition metabolic abnormalities such as wasting and altered energy expenditure are
increasingly recognized as clinical hallmarks of the disease. HD is caused by an unstable CAG repeat
expansion in the HD gene (HTT), localized on chromosome 4p16.3. The number of CAG repeats
in the HD gene is the main predictor of disease-onset, but the remaining variation is strongly
heritable. Transcriptional dysregulation, mitochondrial dysfunction and enhanced oxidative stress
have been implicated in the pathogenesis. Recent studies suggest that PGC-1α, a transcriptional
master regulator of mitochondrial biogenesis and metabolism, is defective in HD. A genome wide
search for modifier genes of HD age-of-onset had suggested linkage at chromosomal region 4p16-
4p15, near the locus of PPARGC1A, the gene coding for PGC-1α. We now present data of 2-loci
PPARGC1A block 2 haplotypes, showing an effect upon age-at-onset in 447 unrelated HD patients
after statistical consideration of CAG repeat lengths in both HTT alleles. Block 1 haplotypes were
not associated with the age-at-onset. Homozygosity for the 'protective' block 2 haplotype was
associated with a significant delay in disease onset. To our knowledge this is the first study to show
clinically relevant effects of the PGC-1α system on the course of Huntington's disease in humans.
Background
Huntington's disease (HD [MIM 143100]; http://
www.ncbi.nlm.nih.gov/Omim/) is one of the most com-
mon autosomal-dominant inherited neurodegenerative
disorders. Clinically HD is characterized by motor and
cognitive impairment, accompanied by a variable degree
of personality change and psychiatric illness[1]. Advanced
stages of HD are characterized by severe emaciation,
despite a strong appetite and increased caloric intake[2,3].
HD is relentlessly progressive and patients succumb to the
disease typically 10–25 years after disease onset[1]. In
1993, a CAG trinucleotide repeat expansion encoding an
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elongated polyglutamine tract in the huntingtin (HTT)
protein was found to cause HD[4]. The number of CAG
repeats in the htt gene is the most important, but not the
only determinant of age at onset of HD. Depending on the
populations studied, the number of CAG repeats in htt
accounts for up to 73% of the variance in age at onset[5].
The remaining variation is strongly heritable[6]. Hence,
modifier genes must contribute to the variability in age at
onset of HD. The genetic modifiers identified so far
include the huntingtin associated protein 1 (HAP1) gene
and the ubiquitin carboxy-terminal hydrolase L1
(UCHL1) gene [7-9]. The MAPS study, a genome-wide
scan for modifier genes of age at onset using micro-satel-
lite markers at a 10-cM density, suggested linkage at chro-
mosomes 4p16, 6p21-23 and 6q24-26 and more
marginal associations at several other sites, including
4p15 (marker D4S3403)[10].
Recently, two independent groups presented evidence
that the transcriptional co-regulator peroxisome prolifera-
tor-activated receptor γ (PPARγ) coactiavtor 1α (PGC-1α)
plays a role in the neurodegeneration of HD [11-13].
PGC-1α regulates the expression of mitochondrial
OXPHOS genes and endogenous antioxidants[14,15].
Mutant but not wild-type HTT down regulates the expres-
sion of this gene set[11,12]. Lack of PGC-1α expression
produces a HD-like phenotype in mice and over-expres-
sion of PGC-1α can antagonize mutant HTT toxicity in
vitro  and  in vivo [11,12,16,17].  PPARGC1A, the gene
encoding PGC-1α, is localized on chromosome 4p15.1-2,
a region, in proximity to one of the HD modifier loci iden-
tified in the MAPS genome scan[18]. We therefore
hypothesized that PPARGC1A polymorphisms are associ-
ated with the age at onset in HD patients.
Methods
Clinical resource
We ascertained possible associations of age at onset with
PPARGC1A in an Italian cohort of 449 HD patients. The
age at onset was considered as the time when motor signs
diagnostic of HD were first noted. All patients have been
diagnosed genetically by the same laboratory at the Isti-
tuto Neurologico C. Besta of Milano[19]. As to the clinical
evaluation, 139 patients were neurologically assessed at
the Outpatients Neurogenetic Clinic facility of the C.
Besta Institute (either by Stefano Di Donato, MD, and
Caterina Mariotti, MD, Unit of Biochemistry and Genet-
ics, or Paola Soliveri, MD, Division of Movement Disor-
ders, Istituto Neurologico C. Besta, Milano). The
remaining 310 patients were clinically assessed by expert
neurologists from Italian Neurological Centers other than
the Istituto Neurologico C. Besta, and then referred to us
for molecular diagnosis. As age at onset in HD is difficult
to ascertain, and susceptible to considerable variation on
the basis of environmental and genetic factors[20], we set
the alleged age at onset as the time when motor signs diag-
nostic of HD were first noted. With regard to patients
referred from other neurological centres, we (SD and CG)
carefully re-checked each file for age at onset. For most
patients the presumed motor onset was clearly indicated;
for a minority of patients, however, we found that the
neurological onset came out to be different from the one
suggested by the referring neurologist (possibly indicating
the behavioural-psychiatric onset), and accordingly reset
the disease onset as the age at motor onset.
The population comprised 215 male and 234 female
unrelated HD patients. The mean (SD, median, range) of
age at onset was 48.9 (13.9, 49, 6–80) years. The mean
(SD, median, range) of HD CAG repeat size as determined
in a single diagnostic laboratory was 45.3 (5.5, 44, 37–
90). HD CAG repeat size explained 61% of the variation
in age at onset and no sex-specific difference in age at
onset or HD CAG repeat size was observed.
Genotyping
DNA was isolated from peripheral white blood cells. By
sequencing phased chromosomes and typing eight
informative single nucleotide polymorphisms (SNPs) of
PPARGC1A in various populations, we previously identi-
fied two haplotype blocks, termed block 1 and 2, each
comprising five common haplotypes. The boundary
between the two haplotype blocks is located in intron 2.
Haplotype block 1 extends 20 kb upstream of the transla-
tional start site, while haplotype block 2 extends < 20 kb
beyond the proximal poly A signal[21]. Four SNPs dis-
criminatory for PPARGC1A  haplotype block 1 at gene
positions -3974 A/G (rs2970865), -3833 A/C
(rs1878949), -1694 T/C (rs17576121), and -1437A/G
(rs2970870) as well as four haplotype block 2 SNPs at
gene positions +75657 C/T (rs2970847), +75919 C/T
(rs8192678), +76059 C/T (rs3755863) and 94581 C/T
(rs6821591) were typed in 389 HD patients. SNPs
rs2970847, rs8192678, rs3755863 and rs6821591 in the
coding region correspond to positions +1302, +1564,
+1704 and +2962, respectively, in the mRNA sequence
relative to the translational start site. Among variant sites,
only rs8192678 results in an amino acid change (Gly >
Ser). SNP qualifiers refer to database entries http://
www.ncbi.nlm.nih.gov/SNP/.  PPARGC1A  haplotype
block 1 SNPs were determined using TaqMan Genotyping
Assays (Applied Biosystems, Warrington, UK)
C_1643250_10, C__1643249_10, C_27842167_10 and
C_1643241_10. TaqMan Assays for haplotype block 2
SNPs were PGC1ASNPEI_301 (custom), C_1643192_10,
C_25992571_10 and C_26497328_10, respectively. The
overall genotyping success rate was 99%. Success rates for
all SNPs typed were > 99% with the exception of
rs1878949 which was 96%. In several subjects in whom
typing of rs1878949 was unsuccessful, the presence of theMolecular Neurodegeneration 2009, 4:3 http://www.molecularneurodegeneration.com/content/4/1/3
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region harboring the SNP was verified by sequencing to
exclude major sequence deviations. Correct typing results
were verified in > 15% of subjects by restriction enzyme
digestion and/or sequencing.
Statistics
Associations of SNPs with age at onset of HD were ascer-
tained in linear models. Logarithmically transformed age
at onset was used as the dependent variable and individ-
ual SNPs, normal and expanded CAG repeat sizes as well
as their interactions as independent variables[22]. For
testing associations between haplotypes and age at onset,
we used the haplo.score software, which provides both
global and haplotype-specific tests[23]. Adjustments were
made for normal CAG repeat, expanded CAG repeat size
and their interaction. The THESIAS software http://gene
canvas.ecgene.net/downloads was used to estimate stand-
ardized pairwise linkage disequilibria (LD) expressed in
terms of D', haplotype frequencies and covariate-adjusted
mean effects of haplotypes on logarithmically trans-
formed age at onset.
Results
Distributions of genotypes at all SNPs did not deviate sig-
nificantly from Hardy-Weinberg expectations. As
expected, the pairwise LD matrix revealed two main hap-
lotype blocks, previously identified in other popula-
tions[21]. In each haplotype block, 5 common haplotypes
with frequencies > 0.01 were inferred that accounted for >
97% of the chromosomes. For each of the common hap-
lotypes, the squared correlation between true and pre-
dicted haplotype dose was > 0.97 (Fig. 1). No associations
were observed between block 1 haplotypes and age-at-
onset (data not shown). Rs6821591, located in hap-
loblock 2 in the 3-untranslated region, displayed an asso-
ciation in the dominant model (P  = 0.0178).
Furthermore, global testing suggested an association
between block 2 haplotypes and age at onset (Table 1). In
particular, haplotype-specific statistics scores were highest
and lowest for haplotypes 0001 and 0000, respectively.
The estimated difference in age at onset between these two
haplotypes was 2.8 years. Consequently, rs6821591, dis-
criminating haplotypes 0001 and 0000, was found to be
associated with the age at onset after adjustment for link-
age disequilibrium between the SNPs forming haploblock
2 (P = 0.0025).
Polymorphisms and haplotype blocks in PPARGC1A Figure 1
Polymorphisms and haplotype blocks in PPARGC1A. Linear map with exons (full boxes), SNP positions are relative to 
the translational start site. MAF indicates minor allele frequency; typing studies in other populations showed that, unlike in the 
HD population studied, C > T at rs6821591; SNP qualifiers refer to database entries http://www.ncbi.nlm.nih.gov/SNP/. SNPs 
not used in the initial haplotyping studies are shown above the linear map. The extension of haplotype blocks is shown at the 
bottom. Scales differ for the transcribed sequence and the 5'-untranscribed sequence.Molecular Neurodegeneration 2009, 4:3 http://www.molecularneurodegeneration.com/content/4/1/3
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To identify individual SNPs in this region that may show
stronger associations with age at onset, we searched Hap-
Map, release 21a/phase II http://www.hapmap.org for
SNPs with variant alleles predominantly occurring on
block 2 haplotypes 000X. We identified several SNPs and
typed three such SNPs (rs2970849, rs25935762,
rs31179675) in the 389 HD patients. According to phased
HapMap data, these three SNPS signify distinct clades of
000X block 2 haplotypes. rs2970849 (C/T), located in
intron 7, and rs3736265 (A/G, Thr/Met), located in exon
9, showed no associations with age at onset, irrespective
of the model used (data not shown). However, rs7665116
(A/G), located at the 3'-end of a highly conserved region
in intron 2, revealed a significant association in the addi-
tive and dominant model (both P < 0.002). We therefore
typed rs7665116 in the 60 remaining HD patients. Con-
sidering CAG repeat size in both alleles as well as their
interaction in the 449 study subjects, a significant associ-
ation of rs7665116 with age at onset was observed in both
the additive and the dominant model, and the age of
onset increased by 3.7 or 4 years in going from the A/A to
the A/G or G/G genotypes, respectively (Table 2). The G/
G genotype, which showed the biggest difference in age at
onset, was present in 12 cases. The statistical significance
of the association was maintained after the Bonferroni
correction for the number of SNPs tested (P < 0.02 and P
< 0.005 for additive and dominant models, respectively).
Introducing rs7665116 explained 2.6% of the residual
variance in the model. No interaction of rs7665116 with
HD CAG repeat size was noted.
The linkage disequilibrium between rs7665116 and
rs6821591 was not complete (D' = -0.86). R2 was 0.098,
reflecting the lower frequency of rs7665116. We therefore
typed rs6821591 in the remaining subjects and confirmed
the associations observed in the smaller number of HD
patients (Table 3). We also ascertained associations of
two-loci haplotypes and, as expected, found opposing
associations of haplotypes carrying two wild-type and two
variant nucleotides (Table 4). The estimated difference in
age-at-onset was 2.1 years.
Discussion
Here we report the presence of a common polymorphism
and a common haplotype in PPARGC1A that are associ-
ated with a delay in age at onset of motor symptoms in
patients with Huntington's disease. This clinical finding
complements independent mechanistic studies on trans-
genic animals and human post mortem brain tissue, which
demonstrated that impairment of the PGC-1α system
contributes to the pathology of experimental HD. Lin et
al. showed that mutant htt suppresses the expression of
PGC-1α, while Weydt et al. found that mutant htt can
inhibit the effects of PGC-1α on the expression of its target
genes [12,16]. These two concepts are not mutually exclu-
sive, as PGC-1α may induce its own expression via a feed-
forward loop[15,24]. Our association study in humans
now suggests that PPARGC1A indeed modifies the age at
onset of HD and hence provide critical support for a role
of PGC-1α in the pathogenesis of HD in humans.
It should be noted, that clinical phenotypes reminiscent
of HD have been described without mutations in the HD
gene[25]. Interestingly, chromosomal region 4p15.3 has
been implicated in a recessive, progressive neurodegener-
ative Huntington-like disorder[26] (HDL3 [MIM
604802]; http://www.ncbi.nlm.nih.gov/Omim/). It is
thus possible that "loss of function" mutations in
Table 1: PPARGC1A Block 2 Haplotypes and Age at Onset of HD
Haplotype Frequency Score P
0000 0.234 -2.766 0.0057
0001 0.139 2.633 0.0085
0011 0.080 0.038 0.9698
0111 0.324 -0.192 0.8479
1000 0.204 0.396 0.6923
N = 389; adjusted for CAG repeat size on both alleles (HD and non-
HD) and their interaction;
P = 0.0161 for global haplotype statistics; block 2 haplotypes: 0, more 
common allele
(+1302C, +1564C, +1704C, +2962C); 1, less common allele (+1302T, 
+1564T, +1704C, +2962T).
Table 2: PPARGC1A rs7665116 and Age at Onset in the HD Cohort
rs7665116 genotype
Variable A/A A/G G/G Pa Pb
Sex, m/f 155/157 53/72 7/5 n.s. n.s.
HD CAG 45.3 (5.5) 45.2 (5.9) 45.8 (2.8) n.s. n.s.
Non-HD CAG 18.3 (3.2) 18.5 (3.5) 17.7 (3.9) n.s. n.s.
HD CAG*non-HD CAG 828 (179) 840 (210) 809 (192) n.s. n.s.
HD-onset, yearsc 45.08 (1.43) 48.75 (1.39) 49.09 (1.22) 0.0016 0.0003
a additive model; b dominant model; c calculated from log-transformed years and adjusted for HD CAG and non-HD CAG repeat size and their 
product.Molecular Neurodegeneration 2009, 4:3 http://www.molecularneurodegeneration.com/content/4/1/3
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PPARGC1A can cause a recessive HD-like disease as sug-
gested by gene deletion studies in mice[16,17].
The arguments presented here provide first support from
observations in humans for the concept that PGC-1α fail-
ure contributes to the pathogenesis of HD. If our results
are confirmed in other populations, the identification of
the functional SNP(s) may provide mechanistic insight
into the pathogenesis of HD and may have important
implications for the delineation of therapeutic tar-
gets[27,28].
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